Hypothesis : absence of graft-versus-host disease in AIDS is a consequence of HIV-1 infection of CD4+ T cells
We hypothesize that graft-versus-host disease (GVHD) does not occur in HIV-1-infected subjects because graft cells (or host cells recognizing antigenic differences in other host cells) mediating the graft-versus-host reaction are CD4+ T cells that become infected with HIV-1 and are rendered immunolo...
Gespeichert in:
Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1988) 1993-11, Vol.6 (11), p.1224-1227 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We hypothesize that graft-versus-host disease (GVHD) does not occur in HIV-1-infected subjects because graft cells (or host cells recognizing antigenic differences in other host cells) mediating the graft-versus-host reaction are CD4+ T cells that become infected with HIV-1 and are rendered immunologically incompetent. GVHD has been documented in all forms of genetic or acquired severe T-cell deficiencies, except in patients with AIDS. Its striking absence in multiply transfused patients suggests that HIV-1 infection prevents its occurrence. We propose the following sequence of events. Transfusion of immunocompetent cells into HIV-1-infected subjects results in an in vivo allogeneic cell response. The activated CD4+ T cells become infected with HIV-1 and are rendered immunologically incompetent or are destroyed and cannot, therefore, initiate GVHD. Suggestions have been made by others that a GVHD-like mechanism results from HIV-1 infection and is a potentially important factor in the pathogenesis of AIDS and that, therefore, immunosuppressive therapy should be evaluated in HIV-infected patients. However, since most immunosuppressive therapy cannot be targeted to a specific functional immune cell, and since enhancement of immunity is more likely to prevent many of the complications of HIV-1 infection that ultimately cause death, treatment of HIV-1-infected patients should be directed toward improving immune function rather than immunosuppression. |
---|---|
ISSN: | 0894-9255 1525-4135 2331-2289 1944-7884 |